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Abstract
Worldwide, stroke is the second leading cause of death and a major cause of disability . However, the mortality 
of stroke differs between countries and geographical regions. In high-income countries, i.e. in the United States, 
stroke has fallen from the third to the fourth leading cause of death. The risk for ischaemic stroke increases 
with the degree of internal carotid artery stenosis. 70–99% carotid artery stenosis (according to NASCET) 
in symptomatic patients is an indication for a vascular intervention since this group will achieve significant 
benefits from surgical treatment. Asymptomatic patients with 60–99% (according to NASCET) carotid artery 
stenosis may also benefit from surgical procedures when at least one-factor conditioning a high risk of ischaemic 
stroke incidence exists. These factors may include morphological structure features of atherosclerotic plaque 
described in imaging examinations that are indicative of its instability and specific clinical predispositions. The 
paper presents stages of unstable atherosclerotic plaque development and features of its morphological struc-
ture that may significantly increase the risk for ischaemic stroke and compares them with current guidelines: 
Management of Atherosclerotic Carotid and Vertebral Artery Disease: 2017 Clinical Practice Guidelines of the 
European Society for Vascular Surgery (ESVS).
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Introduction
At present, atherosclerosis constitutes one of the 
main causes of morbidity and mortality in the modern 
population. Since the disease manifests itself clinically 
only in the middle and elderly age, its social and eco-
nomic significance will probably continue to increase 
due to aging of societies. However, studies show that 
early atherosclerotic lesions may be detected in hu-
mans already in their childhood, or even their foetal 
life [1]. Although atherosclerosis is called a civilization 
disease of the 21st century, according to the research 
of American scientists it existed in ancient societies. 
Bodies of mummies that had undergone CT scans 
revealed advanced wall calcifications of large and me-
dium arteries, including carotid arteries. The severity 
of lesions correlated positively with an estimated age 
of the examined individuals at the time of death. These 
discoveries confirmed the fact that modern lifestyle 
is not the only reason for cardiovascular diseases and 
that their incidence may be a consequence of a natural 
process- aging of a human body. It is only the severity 
of atherosclerotic lesions that resembles the influence 
of other contemporary factors [2]. 
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Atherosclerosis of large arteries, including carotid 
arteries, exerts a profound influence on public health. 
Stroke-associated mortality amounts to 10–30% 
and the patients who survived an ischaemic stroke 
are subject to subsequent ones [3]. According to 
a NASCET’s study (The North American Symptomatic 
Carotid Endarterectomy Trial), in symptomatic patients, 
the risk for ipsilateral recurrent ischemic stroke amounts 
to 13% for stenosis above 70%, and 4.4% for stenosis at 
the level of 50–69% per year [3]. Among asymptomatic 
patients with stenosis at the level of 60% and higher, the 
risk for ischaemic stroke reaches 1–2% per year [3]. 
However, the risk may be much higher in case of pa-
tients with the high-risk asymptomatic carotid artery 
stenosis (ACS) i.e. patients with specific characteristics 
regarding morphological structure of atherosclerotic 
plaque, and some clinical predispositions [4].
Over the years, indications for carotid artery steno-
sis surgical treatment have changed significantly [4]. The 
main criterion considered is the degree of an internal 
carotid artery stenosis. The severity of atherosclerot-
ic lesions may be determined by applying numerous 
invasive and non-invasive diagnostic methods, which 
evaluate the degree of stenosis in percentage (%). 
However, presently it is suggested that the best way 
of estimating the risk for ischaemic episodes is the 
evaluation of internal carotid artery stenosis expressed 
as a percentage (%) accompanied by a patient’s history 
with regard to past ischaemic strokes (documented 
ischaemic stroke or transient ischaemic attack) within 
the last 6 months, and evaluation of plaque morphology 
in terms of its instability. These changes are reflected 
in the current guidelines of the European Society for 
Vascular Surgery [5].
Risk factors for atherosclerosis
Atherosclerosis is defined as a chronic inflammatory 
response to a trigger factor damaging the arterial en-
dothelium with phases of period activity, differentiated 
into the stages of development, severity, and extent. 
Atherosclerotic lesions develop mainly where the 
disturbed flow (shear stress) creates an atheroprone 
environment, especially in large arteries (aorta and 
branches), where blood pressure is high and the blood 
flow is not laminar — especially at the sites where 
arteries branch off [6]. Given the above mechanisms, 
the bifurcation of the common carotid artery is one 
of the sites that are mostly predisposed to develop 
atherosclerotic lesions. 
Strongly documented modifiable factors that may 
potentially damage vascular endothelium include hyper-
glycemia, high blood homocysteine level, abnormal lipid 
profile, hypertension and smoking. Documented factors 
that cannot be controlled include age, male sex, and 
genetic factors that are frequently highlighted by many 
authors. Moreover, the following factors are suggested 
to be taken into consideration: deficit of certain vitamins 
and microelements in diet, low physical activity, excess 
weight and obesity, changes in hormone panel occurring 
in people due to aging, exposure to chronic and severe 
stress, and also some infective factors [7].
Genetic factors include not only genetically-deter-
mined familial hypercholesterolaemia, but also coag-
ulation disorders, and indirectly genetic disorders of 
renin-angiotensin–aldosterone system (RAAS) leading 
to arterial hypertension, which is a significant risk factor 
for atherosclerosis as it creates conditions of turbulent 
blood flow [8]. Genetically-determined immunological 
disorders leading to exacerbation of inflammation 
within the arterial wall are also important factors. 
DEGs (differentially expressed genes) are genes that 
undergo a significantly different expression. Analysing 
differences in DEGs expression allows distinguishing 
between an advanced atherosclerotic lesion and an 
early one [9]. These genes expression changes along 
with the plaque developmental stage [9]. In most cases 
DEGs are related to immune response and maintain 
chronic inflammatory process, wich indicates a signifi-
cant role of the immune response in the pathogenesis 
of atherosclerosis [9]. The analysis of DEGs profile in 
atherosclerotic carotid plaque revealed that upregulat-
ed genes were associated with inflammatory response 
and chemotaxis signal pathways within the immune 
system [10]. Downregulated genes were associated 
with contraction and cellular cytoskeleton structure 
of the vascular smooth muscle cells [10]. Furthermore, 
the analysis of DEGs showed that genes associated with 
antigen presentation are of key importance in develop-
ment of atherosclerotic lesions [9]. Some DEGs may 
be a potential therapeutic targets [9].
The beginning 
Endothelium that lines arterial walls is a structure 
whose function influences the balance between coagu-
lation and fibrinolysis, functions of the immune system, 
regulation of arterial blood pressure, and angiogenesis 
[11, 12]. Endothelial cells are highly differentiated and 
specializedwhile having a limited ability to regenerate. 
An important function of the arterial endothelium is to 
secrete factors responsible for vasoconstriction and 
dilatation to maintain proper arterial wall tone, which 
is mostly dependent on the normal secretion of nitric 
oxide (NO) acting as a counterbalance for angiotensin 
II and endothelin I [12]. During the initial stage of 
atherosclerotic plaque formation, disadvantageous 
conditions of blood flow influence the endothelium. 
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Two biomechanical forces acting on the surface of 
arterial walls tensile stress and shear stress. The latter 
is important in the view of atherosclerotic pathomech-
anism. Atherosclerotic plaque forms in very specific 
places, i.e. internal curvature of vessels, bifurcations and 
origin sites of lateral branches, where oscillatory shear 
stress act. The above shear stress leads to endothelial 
damage [13].
A layer of endothelial cells forms a highly specialized 
surface that has direct contact with blood. By continual 
exposure to cells and substances contained in blood, 
the endothelium secretes a number of molecules and 
factors regulating functions of the vascular walls de-
pending on the prevailing conditions [14]. Significant 
lesions in endothelial cells precede atherogenesis [14]. 
Endothelial cells, which are subject to changes in hae-
modynamic and physicochemical conditions, undergo 
functional disorders mainly with regard to the secre-
tion of endothelial nitric oxide synthase (eNOS) that 
is responsible for NO production in endothelial cells 
from L-arginine[14]. 
NO is a gas non-persistent molecule, however, it 
quickly penetrates into the vascular wall, where it influ-
ences the arterial smooth muscle cells while ensuring 
proper arterial wall tone [15]. In addition, NO inhibits 
leucocyte and blood platelet adhesion to the endothe-
lium, stimulates reconstructive processes within the 
endothelium, and inhibits smooth muscle cell migration 
from the tunica media to the tunica intima [15].
Healthy endothelium preserves the balance in terms 
of contractile function and counteracting potential 
inflammation of the arterial wall [16]. A decreased 
NO level leads to many pro-atherogenic phenomena, 
such as intensified vasoconstriction, increased blood 
platelet aggregation in the endothelium, oxidative 
modification of lipoproteins accumulated in the tunica 
intima, pro-proliferative [17] and pro-migratory effects 
towards vascular smooth muscle cells (VSMCs) [18], 
as well as adhesion and infiltration of the endothelium 
by monocytes and lymphocytes, which then, migrate 
to the subendothelial space and initiate local inflam-
mation [19].
Factors that damage the endothelium and initiate 
chronic inflammation lead to the gradual degradation 
of the arterial wall. A process of atherosclerotic lesion 
formation starts with a pathologic intimal thickening 
[20, 21]. The first phenomenon that appears in the 
process of the atherosclerotic lesion formation is adap-
tive thickening of the intima that is caused by VSMCs 
accumulated in proteoglycan-rich matrix [20], what in 
turn leads to thickening of the intima media complex. 
These sites are predisposed to atherosclerotic plaque 
formation [21] (Fig. 1).
Plaque development
lipid metabolism disorders influence the change in 
the function and structure of endothelial cells. In case of 
hypercholesterolaemia, endothelial cells (ECs) change 
their structure [14]. Endothelial cells subject to contact 
with blood rich in cholesterol and triglycerides change 
their phenotype into a secretory phenotype [14]. 
Figure 1. Intima-media thickening (ultrasound picture: A. Płoński)
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Connections between cells become more permea- 
ble [14]. Shear stress forces acting on vascular walls 
facilitate permeation of low-density lipoproteins (LDL) 
through the tunica intima by increased pressure and 
causes repetitive microtrauma in the arterial endothe-
lium [14]. Low-density lipoproteins (LDL), which 
transport cholesterol to tissues, may bond with arterial 
proteoglycans by means of apolipoprotein B (a protein 
component of LDL) [22]. Minimally modified LDL 
(mmLDL) permeate the subintimal space. Lipoproteins 
that accumulate under the endothelial layer undergo nu-
merous modifications and are oxidized to oxLDL [23]. 
Moreover, lipoproteins may permeate the subintimal 
space via transcytosis. Endothelial cells, inside which 
lipoproteins are confined, cumulate lipids and become 
endothelial-derived foam cells [24].
Adhesion molecules [ICAM (intercellular adhesion 
molecule) VCAM (vascular cell adhesion molecule)] that 
appear on the endothelial surface allow for monocyte 
infiltration of the subintimal space; the monocytes aim at 
eliminating oxidized lipoproteins [25]. Monocytes trans-
form into macrophages, which bind large numbers of 
oxLDL by SR receptors (scavenger receptors) while ab-
sorbing them and becoming foam cells [25]. The above 
changes form fatty streaks in vascular walls [26] that in 
fact are accumulated foam cells within the tunica intima. 
Foam cells (derived mainly from macrophages, but also 
from VSMCs, and ECs) [24], with autophagy defect, are 
characterized by accumulation of damaged organelles, 
what leads to cell death [27] with subsequent release 
of its content, including accumulated lipids.
When macrophages undergo apoptosis, their cho-
lesterol-rich content gets out into the extracellular 
space [27]. Chemotactic signals attract other mac-
rophages what leads to a vicious circle and gradual 
formation of a necrotic core [27] between the internal 
and external elastic lamina, which contains mainly lipids 
and disintegrated dead cells.
Lipids accumulate in cells and extracellularly. Vascu-
lar smooth muscle cells (VSMCs) are attracted to these 
sites [28]; they migrate from tunica media to tunica 
intima drawn by a chemotactic signal of T-lymphocytes 
that secrete interferon gamma (IFN gamma) [28]. 
VSMCs that moved into the tunica intima change their 
phenotype in order to repair damaged vascular wall 
— from a cell that is able to contract into a cell that 
has an ability to proliferate and secrete extracellular 
matrix. Having changed the phenotype, VSMCs produce 
extracellular matrix to stabilize the formed change and 
limit the inflammation within it [28]. Extracellular matrix 
consists of connective tissue parts, such as collagen and 
proteoglycans that are deposited within the plaques, 
predominantly close to its surface, where the fibrous 
cap is formed. Strength of the protective fibrous cap 
depends on its structure conditioned by type 1 and type 
3 collagen [28]. At an advanced stage of atherosclerotic 
plaque development, VSMCs play an important protec-
tive function. Their presence is of key importance in 
the process of fibrous cap formation and maintaining 
its proper thickness [29]. A fibrous cap maintains the 
plaque integrity and separates lipid-rich and thrombo-
genic content of the core from the arterial lumen [28]. 
Atherosclerotic plaque growth and development 
takes place over many years. A microscopic cross-sec-
tion of the plaque shows its history, in which the 
following foci may be observed: neovascularization, in-
traplaque haemorrhage [IPH] and thrombus formation. 
Development of atherosclerosis leads not only to arte-
rial stenosis but also it remodels the arterial wall [30]. 
Such remodelling may have a significant influence on 
the clinical presentation of the disease. In some cases 
the plaque may not grow concentrically narrowing the 
vascular lumen, but spread eccentrically. It results from 
an increased blood flow velocity through the artery due 
to stenosis progression and acting shear stress [30]. In 
such conditions, the endothelium secretes considerable 
amounts of nitric oxide. NO causes a compensatory 
dilation of the lumen that becomes permanently re-
modelled over time [30]. Such a type of atherosclerotic 
plaque may not cause a hemodynamically significant 
arterial stenosis for many years. This phenomenon is 
called a positive remodelling of a vascular wall [30]. 
Negative remodelling is a decrease in a vascular di-
ameter due to arterial wall fibrosis being a result of 
a long-lasting atherosclerotic process which leads to 
a faster stenosis progression and plays an important 
role in a restenosis mechanism after percutaneous 
transluminal angioplasty (PTA) procedures [30].
Atherosclerotic plaque instability
Stability of atherosclerotic plaque is ensured by 
a thick fibrous cap with high collagen content, a con-
siderable amount of extracellular matrix, small necrotic 
core and calcifications (Fig. 2). Moreover, plaque sta-
bility depends on the level of its infiltration through 
inflammatory cells [31].
Unstable plaque may be described as plaque that 
through a sequence of events may lead to ischaemia 
of tissues supplied by an atherosclerotic artery. It is 
a plaque that may lead to ischaemic episodes and clinical 
consequences. Unstable plaque in the carotid artery 
can be defined as a plaque in which specific features of 
morphological structure predisposing it to embolization 
with thrombogenic material are confirmed. Unstable 
plaque is characterized by a large lipid core that is 
a result of lipid accumulation in cells and extracellularly, 
as well as a thin fibrous cap deficient in collagen fibres [31] 
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(Fig. 3). American Heart Association (AHA) classifies 
unstable plaque as type 5 and 6 [32] (Table 1).
As a result of enlarging necrotic core, the cap un-
dergoes gradual thinning associated with its stretching. 
The cap may be also thinned as a result of increased 
degradation of collagen fibres within it. This is caused 
by the activity of matrix metalloproteinases (MMPs) 
released by macrophages activated by chemotactic 
factors [28]. Furthermore, the structure of fibrous cap 
may be weakened when collagen production decreases 
due to apoptosis of a large number of VSMCs [28]. 
Some authors claim that aggrecan deposits (mainly 
proteoglycan) may induce VSMCs apoptosis [33]. 
In balanced conditions, healthy endothelium se-
cretes large amounts of NO that stimulates aggrecanase 
function – an enzyme that decomposes aggrecan de-
Figure 2. Stable calcified carotid atherosclerotic plaque (ultrasound picture: A. Płoński)
Figure 3. Unstable „soft” carotid atherosclerotic plaque (ultrasound picture: A. Płoński)
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posits [33]. When the endothelium is damaged, mRNA 
coding large amounts of proteoglycans, especially 
aggrecan, undergoes overexpression. Subendothelial 
aggrecan leads to increased uptake of large numbers of 
lipoproteins, and to an increased VSMCs apoptosis [33]. 
VSMCs that undergo apoptosis in large numbers lead 
to a decrease in production of collagen and other 
components of extracellular matrix, exacerbation of 
existing inflammation, and further enlargement of 
plaque necrotic core, in which residues of disintegrated 
cells cumulate [28].
Unstable plaque is characterized by a higher level of 
VSMCs apoptosis than stable plaque. Moreover, over 
time VSMCs apoptosis leads to calcifications within the 
plaque [34]. The above phenomena weaken the struc-
ture of the fibrous cap, especially within the weakest 
point of its structure called a cap shoulder. The cap 
shoulder, where VSMCs are in minority and macrophag-
es in the majority, is the place where plaque rupture 
occurs most frequently [35]. Thinning of the fibrous cap 
in carotid atherosclerotic plaque is an independent risk 
factor for ischaemic episodes [36]. A large necrotic core 
contains a large number of accumulated lipids and free 
cholesterol, which undergoes crystallization and causes 
an increase in plaque volume as well as stretching of the 
fibrous cap, what may lead to it being damaged [37]. In 
addition, fissures in the cap are associated with parallel 
arrangement of cholesterol crystals in the core [37] 
what reflects high blood pressure in the artery. Some-
times also asymptomatic silent plaque ruptures occur. 
VSMCs repair the damage and reorganize the blood clot 
that appeared [38]. In histopathological examinations, 
advanced atherosclerotic plaque shows numerous rup-
ture and repair sites, which leads to a gradual accretion 
of the plaque to the inside of the vessel and progressing 
stenosis [38]. A damage repair process requires active 
VSMCs proliferation and intense matrix production, 
which may be insufficient considering the advanced 
VSMCs apoptosis [39].
Inflammatory cells play a crucial role in both plaque 
formation and complications resulting from athero-
sclerotic plaque development. Inflammatory cells such 
as macrophages and T-lymphocytes are present in 
plaque at every stage of its development and exhibit 
features that destabilize the plaque, what is associated 
with an uncontrollable secretion of large quantities of 
IFN gamma by T-lymphocytes (CD4+ CD28–) [40]. 
Additionally, these cells damage endothelial cells in 
a direct way. It has been shown that activated mac-
rophages and myocytes present in plaque show MHC II 
(Major Histocompatibility Complex II) expression 
[41]. They have an ability to present antigen to the 
T-lymphocytes [41]. Lymphocyte activation involves 
secretion of pro-inflammatory cytokines and intensi-
fication of the inflammatory response in the vascular 
wall. Pro-inflammatory cytokines, released in the 
atherosclerotic plaque, exert both local and systemic 
effects [42]. They stimulate the liver to synthetize 
proteins being inflammatory state markers (CRP, fi-
brinogen) [42]. IFN gamma secreted by T-lymphocytes 
stimulates macrophages to secrete MMPs. MMPs sig-
nificantly destabilize the plaque in subsequent stages of 
its development [43, 44]. 
ICAM-1 (intercellular adhesion molecule) and 
LFA-1 (lymphocyte function associated molecule) are 
key molecules participating in adhesion and migration 
of inflammatory cells [45]. Expression of these mol-
ecules correlates positively with the level of plaque 
macrophage infiltration and the level of T-lymphocyte 
migration to the tunica intima [45]. Plaque destabiliza-
tion takes place due to the intensification of a chronic 
inflammatory process within the plaque and substantial 
infiltration by the mentioned inflammatory cells with all 
consequences of the process [45].
Table 1. AHA classification of atherosclerotic plaque (conventional and modified classification for MRI) [32]
Conventional AHA Classification Modified AHA Classification for MRI
Type I: Initial lesion with foam cells Type I–II: near — normal wall thickness, no calcification
Type II: Fatty streak with multiple foam cell layers
Type III: Preatheroma with extracellular lipid pools Type III: diffuse intimal thickening or small eccentric plaque 
with no calcification
Type IV: Atheroma with a confluent extracellular lipid core Type IV–V: plaque with a lipid or necrotic core surrounded 
by fibrous tissue with possible calcificationType V: Fibroatheroma
Type VI: Complex plaque with possible surface defect,  
hemorrhage, or thrombus
Type VI: complex plaque with possible surface defect,  
hemorrhage, or thrombus
Type VII: Calcified plaque Type VII: Calcified plaque
Type VIII: Fibrotic plaque without a lipid core Type VIII: Fibrotic plaque without lipid core  
and with a possible small calcification
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Unstable plaque is often confirmed to have in-
traplaque haemorrhage originating from pathological 
spread of vasa vasorum [46], or ulcerations [47] (Fig. 4). 
Fragile vasa vasorum, which develop as a result of hy-
poxia, are the main source of intraplaque haemorrha- 
ges [46]. An intraplaque haemorrhage (IPH) predicts 
an episode of cerebral ischaemia [47]. Furthermore, 
it is a factor predisposing for a recurrent cerebral 
ischaemic episode [48]. Upon MRI imaging [49] IPH is 
more often revealed in symptomatic patients [47, 50]. 
Abnormal vessels formed during neovascularization 
may rupture spontaneously or may lead to chronic 
intraplaque haemorrhage. Intraplaque haemorrhages, 
together with cell apoptosis, play an important role 
in necrotic core development [49]. Haemoglobin re-
leased from erythrocytes destabilizes plaque [49] due 
to induction of inflammatory state. Iron released from 
haemoglobin forms deposits, while causing a formation 
of large amounts of reactive oxygen species (ROS) [51], 
what in turn leads to oxidative stress, and significantly 
destabilizes the plaque. An intraplaque haemorrhage 
classifies plaque as type 6b according to AHA classifi-
cation [52] (Table 1).
 Haptoglobin (Hp) is a key protein that binds free 
haemoglobin and protects from the consequences of 
its release. In addition, haptoglobin promotes biding 
the haemoglobin by scavenger receptors on the sur-
face of macrophages [53]. It is believed that genetic 
polymorphism (two alleles) of Hp influences its anti-in-
flammatory and anti-oxidative response to intraplaque 
haemorrhages. In the case of Hp 2-2 genotype, a greater 
risk for cardiovascular diseases, including atherosclero-
sis, is observed [53].
An increased amount of aging cells is detected in 
atherosclerotic plaque, what is confirmed in studies on 
specific markers such as SaG (senescence-associated ga-
lactosidase), whose significant increase is noticed within 
atherosclerotic plaque as compared with a healthy vas-
cular wall [54]. Cell aging within a lesion may be divided 
into 2 types: replicative and inductive. The first one is 
characterized by telomere shortening at the edges of 
chromosomes. The second type is induced by external 
factors, e.g. oxidative stress or ionizing radiation, and 
leads to premature cell aging [54]. Repair of plaque 
damages requires VSMCs replication, however, the 
more advanced the process of atherosclerotic plaque 
development, the higher the level of VSMCs aging [54]. 
Within the cap shoulder, there is a larger number 
of aging cells exhibiting telomere shortening [55] and 
a decreased level of sheltering proteins, such as TRF-2 (telo - 
meric repeat-binding factor-2), what leads to increased 
DNA damages as compared with cells from a healthy arte-
rial wall [56]. Aging VSMCs have limited replication abilities 
and an increased number of immune receptors, and thus, 
generate a highly pro-inflammatory environment [57]. 
Regulating the balance between cell death and aging, as 
well as proliferation and migration are of key importance 
in atherogenesis and maintaining plaque stability.
Many scientists confirmed cell apoptosis within 
plaque [58]. As the plaque develops, the cell apop-
Figure 4. Unstable carotid plaque with ulceration (ultrasound picture: A. Płoński)
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tosis increases. In advanced atherosclerotic plaque, 
extracellular matrix separates cells from each other 
and limits their migration and phenotype changes. 
Macrophage-infiltration of the plaque leads to matrix 
degradation, promotion of VSMCs phenotype changes, 
and migration of both cell types [59]. Changes in cell 
phenotype often led to their incorrect identification: 
both in cases of VSMCs that changed their phenotype to 
macrophage-like cells, and macrophages that changed 
their phenotype to VSMCs-like cells [59, 60].
VSMCs, which so far played a stabilizing and protec-
tive role in the advanced stage of plaque development, 
may change their phenotype to macrophage-like cells 
that induce inflammatory state [59, 60]. In VSMCs, 
genes responsible for facilitating phagocytosis un-
dergo expression, however, their expression in mac-
rophage-like cells is weaker than in macrophages, and 
consequently, it is conducive to further accumulation 
of cell residue [59–61].
Within an advanced atherosclerotic lesion, a reverse 
phenotype change may also occur – macrophages 
change into VSMCs-like cells. Despite numerous re-
ports on the importance of VSMCs in the stabilization 
of atherosclerotic plaque [61], studies showed that 
VSMCs- like cells and being in reality bone marrow- 
-derived cells have the potential to destabilize the plaque 
as opposed to VSMCs derived from arterial walls [62].
Risk evaluation
current guidelines- Management of Atherosclerotic 
Carotid and Vertebral Artery Disease: 2017 Clinical 
Practice Guidelines of the European Society for Vascular 
Surgery (ESVS 2017) [1] indicate groups of patients 
that may achieve the greatest benefits from surgical 
treatment, and determine groups of patients that 
should be treated only by best medical treatment (BMT) 
pharmacotherapy. The greatest benefits from surgical 
treatment are achieved by symptomatic patients with 
70–99% carotid artery stenosis (according to NASCET) 
estimated on the basis of CT or MRI scans, or Duplex 
Doppler exam performed twice by independent ul-
trasonographers. Symptomatic patients are defined as 
individuals who had a documented stroke within the 
past 6 months or transient ischaemic attack (TIA). Such 
patients are recommended to undergo classic carotid 
endarterectomy (CEA) (Fig. 5) in combination with best 
pharmacotherapy (BMT), i.e. ASA in the dose of 75 mg 
and statin (recommendation class Ia). In some cases, 
the surgeon may consider carotid artery stenting (CAS) 
in combination with BMT instead of CEA. 
In symptomatic patients with lower stenosis, de-
gree of 50–69%, surgical treatment should be con-
sidered individually since this group will not achieve 
equal benefits from the treatment as the patients with 
stenosis above 70%. In such cases, endarterectomy 
(IIa) is a preferred method. In some cases, CAS (IIb) 
should be considered.
Patients with an occluded or almost occluded inter-
nal carotid artery should not undergo surgical treatment 
regardless of the history regarding past ischaemic epi-
sodes. This group of patients should undergo treatment 
with the use of BMT pharmacotherapy (Ia). However, 
current guidelines show that there is a group of patients 
that is described as patients with high risk for stroke 
despite the negative history of past ischaemic episodes 
during the past 6 months. It is a group of asymptomatic 
patients with a confirmed 60–99% internal carotid 
artery stenosis in imaging examinations who have one 
or more additional factors suggesting a higher stroke 
risk. In these patients, the use of pharmacotherapy 
only may not be sufficient and it is recommended to 
Figure 5. Carotid atherosclerotic plaque: postoperative material (photo: N. Wiśniewska)
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consider surgical treatment [63]. A preferred method 
is carotid endarterectomy (CEA) in combination with 
BMT (IIa) pharmacotherapy. In high-risk cases of CEA 
performance, carotid artery stenting (CAS) (IIb) may 
be considered. 
The Carotid Revascularization Endarterectomy 
versus Stenting Trial (CREST) concluded that there 
was no significant difference in the rates of the primary 
end point between CAS and CEA procedures [64]. 
However, the International Carotid Stenting Study 
(ICSS) showed that CAS was less safe than CEA in 
symptomatic patients [65].
 Present ESVS Guidelines recommend CEA rather 
than CAS as a preferable operative method, but CAS 
may be considered as an alternative to CEA in some 
patients [1].
 Factors that indicate a higher stroke risk include 
specific clinical conditions or morphological features of 
atherosclerotic plaques in asymptomatic patients that 
were so far treated pharmacologically. Stratification of 
surgical risk should include a combination of plaque 
morphological features and the degree of arterial 
stenosis as well as specific clinical data. In recent years 
many studies identified such factors and suggested 
prophylactic surgical interventions before an ischaemic 
episode occurs [63]. 
Current ESVS guidelines list plaque hypoechogenicity 
as a plaque morphological feature that shows its instabil-
ity. Hypoechogenic plaque is associated with significantly 
higher stroke risk (Fig. 3). It was showed that plaque 
hypoechogenicity is associated with a lipid-rich necrotic 
core and/or intraplaque haemorrhage (IPH) [66, 67]. 
Both lipid-rich “soft” necrotic core and intraplaque 
haemorrhage are factors with a documented potential 
to destabilize an atherosclerotic plaque. Furthermore, 
patients with plaque involving a large area of the artery 
are subject to a higher risk of ischaemic episodes. Large 
plaque with an estimated area above 80 mm2 is associated 
with a significantly higher stroke risk [68], what is often 
associated with the presence of a large necrotic core.
Another parameter visible during imaging exami-
nations is juxtaluminal black area (JBA). In ultrasound, 
JBA is visible as a hypoechogenic area of pixels without 
a visible cap with a greyscale value < 25 adjacent to the 
arterial lumen [69]. The area indicated a considerable 
thinning or loss of cap continuity at its shoulder. It is 
an area whose size is directly associated with a risk 
for the stoke. JBA > 8 mm2 is suggested to be a cut-
off point [69]. This parameter may be used to isolate 
a group of asymptomatic patients with a high risk for 
stroke; also, JBA ultrasound evaluation may help to avoid 
unnecessary surgery in asymptomatic patients [70]. 
The Asymptomatic Carotid Stenosis and Risk of Stroke 
(ACSRS) study confirmed a connection between JBA 
and its size with high stroke risk. Weak points or deficits 
in the structure of the fibrous cap, especially in the cap 
shoulder region, are associated with a high embolization 
potential of the plaque [69].
Intraplaque haemorrhage (IPH) can be evaluated 
using a simple MRI examination. IPH is considered as 
a plaque instability factor and is a feature predisposing 
for ischaemic stroke. A meta-analysis [71] showed 
a strong predictive value of IPH and the presence of 
a large lipid core as well as a thin/ruptured fibrous cap 
confirmed upon the MRI exam.
Another group of patients with a high stroke risk are 
patients with internal carotid artery stenosis in whom 
subsequent examinations confirmed plaque growth and 
stenosis progression ACSRS (The Asymptomatic Carotid 
Stenosis and Risk of Stroke) [72, 73]. In the published 
studies the stroke risk increased with plaque progression 
and also increased proportionally more depending on 
the initial stenosis degree. Patients with a higher stenosis 
degree and its progression were burdened with a higher 
risk than patients with a smaller stenosis degree and its 
progression. Apart from morphological features of the 
plaque, the following clinical data and results of additional 
examination should be taken into account while qualifying 
asymptomatic patients with 60–99% internal carotid 
artery stenosis to a surgical procedure: contralateral 
TIA/stroke, spontaneous microembolization confirmed 
upon transcranial doppler (TCD), silent stroke confirmed 
upon imaging examination, and reduced cerebrovascular 
reserve (CVR) [1].
Conclusion
stroke risk assessment is related to the evaluation 
of atherosclerotic plaque in the internal carotid artery 
in terms of its potential for embolization. Plaque with 
a high potential for embolization is described as unstable 
plaque. Morphological structure of unstable atheroscle-
rotic plaque is reflected in features indicated by ESVS 
and described as high-risk factors for stroke that may 
be confirmed in patients who have been asymptomatic 
so far. Learning about morphological features of ath-
erosclerotic plaque structure that carries the risk for 
embolization has significant clinical implications in the 
process of qualifying patients for surgical treatment. It is 
estimated that from a group of asymptomatic patients, 
about 10–15% of individuals may achieve real benefits 
from a vascular intervention [63]. The results of the on-
going Asymptomatic Carotid Surgery Trial-2 (ACST-2) 
are awaited to estimate the role of the surgical methods 
in the treatment of asymptomatic patients [74]. We 
need more prospective clinical studies conducted on 
a large group of patients, and evaluating the significance 
of particular factors, including morphological structure 
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of the plaque, as well as assessing which surgical meth-
ods in combination with the best pharmacotherapy 
would be the best for this group of patients. 
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